MOLECULAR INFORMATION
Molecular information
- Type
- Short peptide bioregulator · claimed retinal tissue modulator
Normoftal is one of the Khavinson family of “short bioregulator peptides”, targeting retinal / ophthalmological indications.
Claims vs evidence
- Retinal degeneration / age-related macular changes — claimed; no Western RCT
- Post-surgical recovery — single-source data only
Why we grade it D
Same single-source evidence pattern as the rest of the family. See Epitalon for the methodological critique.
Frequently asked questions
- What is Normoftal?
- A short Khavinson-family bioregulator peptide marketed for retinal / ophthalmological indications. Claims include age-related macular changes, retinitis pigmentosa support, and post-surgical recovery.
- Is Normoftal authorised for ophthalmological use?
- No — not authorised by any major regulator. Russian-origin grey-market product without Western clinical trials.
- Why grade D?
- Same single-research-group evidence pattern as the rest of the Khavinson peptide family.